IOVANCE BIOTHERAPEUTICS, INC. has recently released its 10-K report, revealing significant insights into the company's financial condition and operations. The company, headquartered in San Carlos, California, is a commercial-stage biopharmaceutical firm specializing in the development and commercialization of cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
The 10-K report discusses the company's forward-looking statements, including its plans, objectives, expectations, and intentions. It highlights IOVANCE's mission to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. The report also emphasizes the company's commercial products, Amtagvi® (lifileucel) and Proleukin® (aldesleukin), and its ongoing registrational trials in various cancer treatment settings.
The report outlines IOVANCE's corporate strategy, focusing on its mission to be the global leader in innovating, developing, and delivering TIL cell therapy. It emphasizes the company's commitment to continuous innovation to develop TIL cell therapies and optimize TIL treatment regimens to extend and improve the lives of cancer patients. The report also details the U.S. commercial launch of Amtagvi®, the first one-time, individualized T cell therapy approved for the treatment of adult patients with previously treated advanced melanoma.
Additionally, the report delves into the scalable TIL manufacturing capabilities of IOVANCE, highlighting the Iovance Cell Therapy Center (iCTC) in Philadelphia, Pennsylvania, as the first FDA-approved facility to manufacture commercial TIL cell therapy. The report also discusses the company's intellectual property portfolio, consisting of more than 90 U.S. patents related to TIL cell therapy and its T cell-based immunotherapy technology platform.
Furthermore, the 10-K report provides insights into the company's revenue, primarily driven by product sales of Amtagvi® and Proleukin®, and its costs and expenses, including the cost of sales, reserves for excess and obsolete inventory, and royalties payable on the sales of its products.
Today the company's shares have moved 6.31% to a price of $2.36. For the full picture, make sure to review IOVANCE BIOTHERAPEUTICS, INC.'s 10-K report.
